The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction.
 
Maysa M. Abu-Khalaf
Consulting or Advisory Role - Agendia; AstraZeneca; Athenex; Biothera; bioTheranostics; Eisai; Immunomedics; Novartis; Pfizer; Puma Biotechnology
Research Funding - AstraZeneca (Inst); Biothera (Inst); Briacell (Inst); Dompé Farmaceutici (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Christos Hatzis
Employment - Bristol-Myers Squibb
 
K. Alex Hodge
No Relationships to Disclose
 
Frances Valdes
Honoraria - Adverum (I); Allegro Ophthalmics (I); Allergan (I); BVI (I); EyePoint Pharmaceuticals (I); Genentech (I); Janssen Biotech (I); Novartis (I); Santen (I); Valeant Pharmaceuticals International (I)
Research Funding - Merck (Inst); Roche/Genentech (Inst)
 
William M. Sikov
Honoraria - UpToDate
Speakers' Bureau - Daiichi Sankyo; Eisai; Lilly
 
Monica M. Mita
Research Funding - Seagen (Inst)
 
Neelima Denduluri
Consulting or Advisory Role - Daiichi Sankyo; Seagen (Inst)
Research Funding - Amgen (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Seagen
 
Kris Awerkamp
No Relationships to Disclose
 
Rita Murphy
No Relationships to Disclose
 
Daniel Zelterman
No Relationships to Disclose
 
Bryant Dunetz
No Relationships to Disclose
 
Emanuel Petricoin
Leadership - Ceres Nanosciences; Perthera
Stock and Other Ownership Interests - Avant Diagnostics; Ceres Nanosciences; Perthera
Consulting or Advisory Role - Avant Diagnostics; AZGen; Ceres Nanosciences; Perthera
Research Funding - Abbvie (Inst); Ceres Nanosciences (Inst); G1 Therapeutics (Inst); Genentech (Inst); Mirati Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - NIH Patents Licensing Fee Distribution/Royalty; University assigned patent licensing fee/royalty
Travel, Accommodations, Expenses - Ceres Nanosciences; Perthera
 
Mariaelena Pierobon
Stock and Other Ownership Interests - Theranostics Health
Research Funding - Mirati Therapeutics
Patents, Royalties, Other Intellectual Property - AVANT; AVANT